Who are Fulvestrant plus Goserelin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fulvestrant-plus-goserelin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Fulvestrant plus Goserelin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fulvestrant plus Goserelin (Fulvestrant plus Goserelin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen receptor antagonist and gonadotropin-releasing hormone receptor antagonist. Area: Oncology.

phase 2 Estrogen receptor antagonist and gonadotropin-releasing hormone receptor antagonist Estrogen receptor, Gonadotropin-releasing hormone receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Fulvestrant plus Goserelin (Fulvestrant plus Goserelin) — Samsung Medical Center. Fulvestrant is a selective estrogen receptor degrader that inhibits estrogen receptor-positive breast cancer cell growth, while Goserelin is a gonadotropin-releasing hormone receptor antagonist that suppresses estrogen production.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fulvestrant plus Goserelin TARGET	Fulvestrant plus Goserelin	Samsung Medical Center	phase 2	Estrogen receptor antagonist and gonadotropin-releasing hormone receptor antagonist	Estrogen receptor, Gonadotropin-releasing hormone receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Estrogen receptor antagonist and gonadotropin-releasing hormone receptor antagonist class)

Samsung Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fulvestrant plus Goserelin — Competitive Intelligence Brief. https://druglandscape.com/ci/fulvestrant-plus-goserelin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab